MIBG for Refractory Neuroblastoma and Pheochromocytoma

Inclusion Criteria: * Diagnosis: * Relapsed/refractory neuroblastoma with original diagnosis based on tumor histopathology or elevated urine catecholamines with typical neuroblastoma cells in the bone marrow * Metastatic pheochromocytoma * Age \>1 year and able to cooperate with radiation safety restrictions during therapy period * Karnofsky or Lansky performance status of ≥ 50% * Life expectancy: ≥ at least 8 weeks * Disease status: Failure to respond to standard therapy or development of progressive disease at any time. * Disease must be evaluable by MIBG scan. A positive MIBG scan must be present within 8 weeks prior to study entry and subsequent to any intervening therapy. If the patient has only one MIBG positive lesion and that lesion was radiated, a biopsy must be done at least 4 weeks after radiation was completed and must show viable neuroblastoma. * Stem Cells: Patients must have a hematopoietic stem cell product available for reinfusion after MIBG treatment at doses of \> 12 mCi/kg. * Have acceptable organ function as defined below within 7 days of enrollment: * Bone Marrow: ANC ≥750 X 109 /L and platelets ≥50,000 X 109 /L without transfusion if stem cells are not available (any ANC or platelet allowed if stem cells available) * Renal: Creatinine ≤3x upper limit of normal * Hepatic: Bilirubin ≤2x upper limit of normal; AST/ALT ≤10x upper limit of normal * Cardiac: Ejection fraction ≥45% on echocardiogram * Pulmonary: normal lung function as manifes…